Supporting Japan Applications With U.S. Data Is Slower, But Worth It – AGA
This article was originally published in The Gray Sheet
Executive Summary
AGA Medical will support its second regulatory application in Japan with U.S. data - despite the Japanese health ministry's preference for domestic data - because Japanese trials are prohibitively expensive, according to CEO Franck Gougeon